Here at ShareVault we know that growing a life science company isn't easy. Sometimes it feels like a lonely battle when you’re trying to secure the goods and services your company needs to survive. Why go it alone? The Biotechnology Industry Organization (BIO) has created the industry’s largest cost-saving program: BIO Business Solutions®.
According to TechTarget, "Rogue IT" is the use of unsanctioned information technology resources within an organization. Is your company heading down the slippery slope of rogue IT? Are your employees downloading unauthorized apps on personal devices or using Dropbox, Google Docs, or other SaaS platforms that can lead to document leakages, lost business and financial penalties? When employees begin relying on their personal smartphones and cloud apps to get “anywhere, anytime” access to company systems and data, they no longer see the need for the IT middleman. It’s known as “Shadow IT” and it’s definitely a problem in today’s enterprise. Enterprise IT vendor harmon.ie recently ran a competition to highlight the problem. They asked participants to provide the best (or worst, depending on your perspective) example of rogue IT gone wrong. Here are the winners:
February 22 – 25, 2015—Hyatt Regency, New Orleans
Crawfish Étouffée anyone? One of the best reasons to visit New Orleans is that you get to try authentic food that you can’t find anywhere else in the country. But for us here at ShareVault, the New Orleans’ cuisine is just a bonus—our primary interest is attending the Association of University Technology Managers Annual Meeting and to introduce its members to ShareVault’s secure document sharing platform.
We’re excited to be attending this year’s BIO CEO & Investor Conference February 9-10 at the Waldorf Astoria in New York. We hope you’ll be there too and that we’ll have the opportunity to meet. If you haven’t yet registered, you can do so below. Don’t miss this important opportunity to connect with the great mix of investors attending the event.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because BIO's mission is to support industry-wide success, this conference presents a broad and unbiased view of investment opportunities. And, qualified investors can attend for free!
After extremely weak performance in early 2014, the biotechnology industry understandably dropped off the radar of many investors. And, even though the industry has quietly been making a comeback, cautious investors are still concerned with the volatility in the market.
The fact is, despite the current climate of optimism, raising capital in the biotechnology industry has been especially challenging in the past five years, particularly for early-stage companies. Numerous factors, including a challenging FDA environment upon NDA submission, long timelines to approval and the high rate of drug failure, have contributed to a skeptical venture capitalist view of the sector’s prospects. As a result, emerging growth biotechnology companies are increasingly pursuing alternative financing vehicles, including equity crowdfunding, to advance their drug development programs.
This webinar, which takes place at 6:00 am Pacific Time on Thursday, January 29, will provide insight into unique methods employed when valuing products and companies in biotech. For example: How is a DCF model different for these high growth drug R&D companies? What are Real Options and when should they be used? If you have a background in finance, are new to the world of biotech valuation, or are new to the Real Options approach to valuation, then this webinar is for you.
This BIO-sponsored webinar will feature thought leaders in the investment community who will explore the key components of a compelling investment presentation. Learn to perfect the delivery of your presentation in the board room, at the podium, or in one-on-one meetings. This must-see panel gives the inside scoop on pitching to investors and will feature a live Q&A session.
Based on the white paper by Linda M. Pullan, Ph.D., "How to Win at the Partnering Game"
Biotech companies know that it’s essential to align with strategic partners to advance their drug candidates to market. But for the small biotech company the partnering process can sometimes be daunting. To help make the process easier, we’ve put together a list of the ten most common partnering myths. Avoid the mistakes based on these myths, and you’ll be well on your way to those hot licensing deals.
Myth #1: Later is Always Better
It would be logical to assume that the farther your drug is along the development path the more value you will get in a deal. But for the last five years both upfront payments and total deal values have been larger for deals done during Phase II than for deals done during Phase III.
Investors and partners typically do not determine value based on the stage of development as much as the answers to key efficacy questions, such as:
We’re excited about attending the upcoming Biotech Showcase™ in San Francisco, where we’ll be showcasing the many benefits of using ShareVault for biotech licensing deals and fundraising.